Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 and post-infection irritable bowel syndrome.
The abstract entitled ‘POST-INFECTION IRRITABLE BOWEL SYNDROME IN SARS-COV-2 PATIENTS: THE GI-COVID19 STUDY’ (Abstract no: OP138) was presented at UEG Week, October 8 – 11, 2022.
- What gastrointestinal (GI) symptoms have been associated with COVID-19? (0:27)
- What were the aims and methodology of the GI-COVID-19 study? (1:14)
- What were the findings in terms of prevalence of GI symptoms in patients with COVID-19, and post-infection irritable bowel syndrome? (2:29)
- What were the findings at follow-up and which factors were associated with nausea persistence in COVID-19? (3:28)
Disclosures: Giovanni Marasco has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
Share this Video
Related Videos In Digestive Disorders
LIBERTY-EoE-TREET analysis looking at prior use of topical corticosteroids: Arjan Bredenoord, DDW 2023
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) evaluated the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic oesophagitis. We caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the part C subgroup analysis, which investigated the effect of prior topical corticosteroid use on the efficacy of […]
Dupilumab as a therapeutic option for eosinophilic oesophagitis: Arjan Bredenoord, DDW 2023
Dupilumab is a fully human monoclonal antibody that inhibits the interleukin-4 and interleukin-13 pathways, and has been approved for the treatment of eosinophilic oesophagitis in the USA and Europe. touchIMMUNOLOGY caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the burden of eosinophilic oesophagitis, limitations of current therapeutic options, […]
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!